Login to Your Account

Bench Press

Monday, May 7, 2012

Wortmannin is an inhibitor of PI3 kinase, and sensitizes cells to radiation. But clinical development of the compound has mostly been a bust. Oncothyreon Inc.'s wortmannin derivative PX-866 is in several Phase II monotherapy and combination trials for various cancers, but multiple other derivatives as well as wortmannin itself have failed because they have been poorly soluble, unstable and toxic.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription